Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Cirrhosis and Ascites
NCT05726032Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in Cirrhosis, ascites, sponsored by Yale University. Started Sep 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Cirrhosisascites
Beyond the preview
Go deeper on NCT05726032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726032.